FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:1397-1399 September 28, 2006 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: A 52-year-old man with a 36-year history of type 1 diabetes mellitus complicated by hypoglycemia unawareness received two intrahepatic islet-cell allografts. The glycated hemoglobin value before transplantation was 9.3%. He received 400,000 islet equivalents in the first transplantation and 512,000 in the second transplantation, 5 months later. Grafts were prepared at the Joslin Diabetes Center in Boston. His immunosuppression regimen conformed to the Edmonton protocol.¹

Three weeks after the second graft, exogenous insulin was discontinued. The stimulated C-peptide concentration was 2.89 ng per milliliter. The patient did not receive exogenous insulin for 3 months, but thereafter insulin . . . [Full Text of this Article]

This article has been cited by other articles:

• Vantyghem, M.-C., Kerr-Conte, J., Arnalsteen, L., Sergent, G., Defrance, F., Gmyr, V., Declerck, N., Raverdy, V., Vandewalle, B., Pigny, P., Noel, C., Pattou, F. (2009). Primary Graft Function, Metabolic Control, and Graft Survival After Islet Transplantation. Diabetes Care 32: 1473-1478 [Abstract] [Full Text]  
• Rickels, M. R., Kamoun, M., Kearns, J., Markmann, J. F., Naji, A. (2007). Evidence for Allograft Rejection in an Islet Transplant Recipient and Effect on {beta}-Cell Secretory Capacity. J. Clin. Endocrinol. Metab. 92: 2410-2414 [Abstract] [Full Text]